Tarsus Pharmaceuticals Management
Management criteria checks 4/4
Tarsus Pharmaceuticals' CEO is Bobby Azamian, appointed in Nov 2016, has a tenure of 7.5 years. total yearly compensation is $3.92M, comprised of 15.1% salary and 84.9% bonuses, including company stock and options. directly owns 2.27% of the company’s shares, worth $27.83M. The average tenure of the management team and the board of directors is 3 years and 3.6 years respectively.
Key information
Bobby Azamian
Chief executive officer
US$3.9m
Total compensation
| CEO salary percentage | 15.1% |
| CEO tenure | 7.5yrs |
| CEO ownership | 2.3% |
| Management average tenure | 3yrs |
| Board average tenure | 3.6yrs |
Recent management updates
Recent updates
Tarsus Pharmaceuticals: A Strong Launch For An Under The Radar Name
Mar 08Rainbows and Unicorns: Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Analysts Just Became A Lot More Optimistic
Mar 03
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Mar 01Is Tarsus Pharmaceuticals (NASDAQ:TARS) A Risky Investment?
Feb 28New Forecasts: Here's What Analysts Think The Future Holds For Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)
Nov 12What Does The Future Hold For Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)? These Analysts Have Been Cutting Their Estimates
Aug 16Tarsus files for FDA approval of TP-03 to treat mite infestation in eyelids
Sep 07Need To Know: Analysts Are Much More Bullish On Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Revenues
May 13CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$136m |
| Sep 30 2023 | n/a | n/a | -US$108m |
| Jun 30 2023 | n/a | n/a | -US$91m |
| Mar 31 2023 | n/a | n/a | -US$65m |
| Dec 31 2022 | US$4m | US$590k | -US$62m |
| Sep 30 2022 | n/a | n/a | -US$63m |
| Jun 30 2022 | n/a | n/a | -US$56m |
| Mar 31 2022 | n/a | n/a | -US$44m |
| Dec 31 2021 | US$7m | US$550k | -US$14m |
| Sep 30 2021 | n/a | n/a | -US$10m |
| Jun 30 2021 | n/a | n/a | -US$5m |
| Mar 31 2021 | n/a | n/a | -US$15m |
| Dec 31 2020 | US$3m | US$437k | -US$27m |
| Sep 30 2020 | n/a | n/a | -US$17m |
| Jun 30 2020 | n/a | n/a | -US$7m |
| Mar 31 2020 | n/a | n/a | -US$5m |
| Dec 31 2019 | US$416k | US$300k | -US$5m |
Compensation vs Market: Bobby's total compensation ($USD3.92M) is below average for companies of similar size in the US market ($USD5.72M).
Compensation vs Earnings: Bobby's compensation has been consistent with company performance over the past year.
CEO
Bobby Azamian
7.5yrs
Tenure
US$3,916,280
Compensation
Dr. Bobak R. Azamian, also known as Bobby, MD, Ph D, DPhil, is Co-Founder of Tarsus Pharmaceuticals, Inc. and serves as its President since November 2016. He serves as Chief Executive Officer at Tarsus Pha...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 7.5yrs | US$3.92m | 2.27% $ 27.8m | |
| General Counsel & Corporate Secretary | 3.3yrs | US$2.53m | 0.11% $ 1.3m | |
| Chief Medical Advisor & Director | 3.8yrs | US$376.44k | 0.079% $ 971.7k | |
| CFO & Chief Strategy Officer | 1.1yrs | no data | 0.0019% $ 22.7k | |
| Chief Operating Officer | 3.8yrs | US$2.41m | 0.17% $ 2.1m | |
| Head of Investor Relations | 2.7yrs | no data | no data | |
| Senior Director of Corporate Communications | 2.1yrs | no data | no data | |
| Vice President of Marketing | 2.3yrs | no data | no data | |
| Vice President of Sales | 2.2yrs | no data | no data | |
| Chief Human Resources Officer | 3.3yrs | US$3.21m | 0.090% $ 1.1m | |
| Chief Commercial Officer | 3.8yrs | no data | 0.14% $ 1.8m | |
| Senior Vice President of Corporate Affairs | less than a year | no data | no data |
3.0yrs
Average Tenure
45yo
Average Age
Experienced Management: TARS's management team is considered experienced (3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 7.4yrs | US$3.92m | 2.27% $ 27.8m | |
| Chief Medical Advisor & Director | 2.3yrs | US$376.44k | 0.079% $ 971.7k | |
| Independent Director | 7.3yrs | US$144.44k | 0.36% $ 4.4m | |
| Lead Independent Director | 3.5yrs | US$239.69k | 0.019% $ 227.4k | |
| Independent Director | 4.4yrs | US$139.31k | 0.0053% $ 64.9k | |
| Independent Director | 1.6yrs | US$257.75k | 0.0035% $ 43.3k | |
| Independent Director | 2.8yrs | US$151.56k | 0.0053% $ 64.9k | |
| Independent Director | 3.8yrs | US$142.19k | 0.0079% $ 97.5k |
3.6yrs
Average Tenure
65yo
Average Age
Experienced Board: TARS's board of directors are considered experienced (3.6 years average tenure).